Ovarian Cancer Serum

About Ovarian Cancer Serum

Ovarian Cancer Serum for Oncology Biomarker Research

Our Ovarian Cancer Serum is sourced from IRB-consented donors clinically diagnosed with ovarian cancer. Each sample is processed and frozen within 24 hours of collection to preserve tumour markers, cytokines, and other circulating proteins. Serum is acellular, so this product supports soluble-analyte work rather than cell-based assays.

Ovarian Cancer Biology and Why Serum

Ovarian cancer is a neoplastic disease, and one where circulating protein markers have a long-established role in clinical monitoring and in early-detection research:

• High-grade serous carcinoma is the dominant histotype, and evidence indicates that many of these tumours originate in the distal fallopian tube epithelium rather than the ovarian surface, arising through serous tubal intraepithelial carcinoma precursors
• Near-universal TP53 mutation characterises high-grade serous disease, alongside widespread copy-number instability rather than a small set of recurrent driver point mutations
• Homologous recombination deficiency — through germline or somatic BRCA1/BRCA2 mutation and other repair defects — defines the subgroup sensitive to platinum chemotherapy and to PARP inhibitors
• CA-125 is the established serum marker, used clinically for treatment response and recurrence monitoring; HE4 and the ROMA algorithm are used in the assessment of adnexal masses. None of these are adequate as standalone screening tests, which is why serum biomarker discovery remains active
• Late-stage presentation is the norm, because early disease is largely asymptomatic — the central problem that early-detection biomarker research is trying to solve
• Why serum: serum is the reference matrix for CA-125 and HE4 immunoassays, supports multiplex protein panels, proteomics, and metabolomics, and yields high aliquot counts and serial timepoints from a single donor

Donor Stratification Available

• Histological subtype: high-grade serous, low-grade serous, endometrioid, clear cell, or mucinous
• Stage at collection, from early-stage to advanced or recurrent disease
• BRCA1/BRCA2 mutation status where clinically tested
• Treatment status: treatment-naive, on platinum-based chemotherapy, on PARP inhibitor maintenance, or post-treatment surveillance
• Platinum sensitivity or resistance category where documented
• CA-125 results where clinically measured; age, menopausal status, and race/ethnicity
• Matched healthy female controls and benign gynaecological comparators available

Product Features

• Collected from clinically confirmed ovarian cancer donors
• Processed and frozen within 24 hours of collection
• Research Use Only (RUO)
• Standard and custom aliquot volumes available
• Serial collections from the same donor available on request
• IRB-approved protocols with documented consent

De-identified Donor Data

• Diagnosis confirmation, with histological subtype and stage where documented
• Age, sex assigned at birth, and ethnicity
• Donor-reported allergy and infectious disease history
• Treatment history, tumour marker results, and family history available on request

Applications

• CA-125 and HE4 immunoassay development, validation, and comparison
• Multi-marker panel and algorithm development for adnexal mass assessment
• Early-detection biomarker discovery
• Serum proteomic, glycoproteomic, and metabolomic profiling
• Treatment response and recurrence monitoring biomarker research
• Platinum resistance and PARP inhibitor response biomarker studies
• Circulating cytokine, angiogenic factor, and inflammatory mediator profiling
• Case-control and longitudinal study design with matched controls

Other Ovarian Cancer Specimen Types

• Ovarian Cancer Plasma — anticoagulated matrix, preferred for circulating tumour DNA work
• Ovarian Cancer Whole Blood — fresh, for germline testing and same-day cellular assays
• Ovarian Cancer PBMC — cryopreserved cells for tumour immunology
• Solid Tumor Cancer PBMC — for pan-tumour comparisons

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering and Customization

Ovarian cancer serum is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. For healthy-donor controls and the full specimen range, see our human serum collection.